Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market Report 2026

Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market Overview

• Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests market size has reached to $0.79 billion in 2025 • Expected to grow to $1.49 billion in 2030 at a compound annual growth rate (CAGR) of 13.4% • Growth Driver: Increasing Prevalence Of Cancer Worldwide Fueling The Growth Of The Market Due To Rising Early Detection Demand And Advancements In Liquid Biopsy Technologies • Market Trend: Advancements In Cell-Free DNA (cfDNA) And Methylation-Based Sequencing Technologies Enhancing Early Detection And Diagnostic Accuracy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market?

Multicancer early detection (MCED) DNA blood tests are advanced diagnostic technologies that enable the identification of multiple types of cancer from a single blood sample by analyzing circulating tumor DNA (ctDNA) and other biomarkers. These tests leverage genomic sequencing, artificial intelligence, and bioinformatics to detect cancer signals at early stages, even before symptoms appear. By enabling non-invasive screening and early diagnosis, they improve patient outcomes, support timely intervention, and enhance precision oncology approaches across healthcare systems. The main test types of multicancer early detection DNA blood tests include pan-cancer minimal residual disease early detection tests, targeted multi-cancer panels, and single-cancer deoxyribonucleic acid blood tests. Pan-cancer minimal residual disease early detection tests refer to advanced blood-based screening methods that detect traces of multiple cancer signals at very early or residual stages using circulating tumor-derived genetic material. They use technologies such as circulating cell-free deoxyribonucleic acid methylation profiling, circulating cell-free deoxyribonucleic acid mutation analysis, fragmentomics, multi-analyte approaches, and other epigenomic approaches and they utilize sample types including blood, plasma, and urine. The various applications involved are asymptomatic population screening, diagnostic support, and cancer recurrence monitoring, and they are used by several end users such as reference laboratories, hospital laboratories, clinics, and direct-to-consumer users.

What Is The Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market Growth Forecast?

The multicancer early detection deoxyribonucleic acid (DNA) blood tests market size is expected to see rapid growth in the next few years.It will grow to $1.49 billion by 2030 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to advancements in multi-cancer early detection liquid biopsy technologies, increasing integration of ai-based genomic interpretation platforms, growing adoption of personalized and precision oncology screening programs, expansion of preventive healthcare initiatives and population screening mandates, rising investment in biomarker discovery and cancer genomics research.Major trends in the forecast period include rising adoption of liquid biopsy-based multi-cancer screening for early detection, increasing use of circulating tumor DNA sequencing for non-invasive cancer diagnostics, growing integration of AI-driven biomarker interpretation in cancer risk prediction, expansion of population-wide preventive oncology screening programs, rising demand for minimally invasive blood-based cancer testing over traditional biopsy methods.

Global Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market Segmentation

1) By Test Type: Pan-Cancer Minimal Residual Disease Early Detection Tests, Targeted Multi-Cancer Panels, Single-Cancer Deoxyribonucleic Acid Blood Tests 2) By Technology: Circulating Cell-Free Deoxyribonucleic Acid Methylation Profiling, Circulating Cell-Free Deoxyribonucleic Acid Mutation Analysis, Fragmentomics, Multi-Analyte Approaches, Other Epigenomic Approaches 3) By Sample Type: Blood, Plasma, Urine 4) By Application: Asymptomatic Population Screening, Diagnostic Support, Cancer Recurrence Monitoring 5) By End Users: Reference Laboratories, Hospital Laboratories, Clinics, Direct-To-Consumer Users Subsegments: 1) By Pan-Cancer Minimal Residual Disease Early Detection Tests: Solid Tumor Detection Panels, Hematological Cancer Detection Panels, Early Stage Cancer Screening Panels, Late Stage Cancer Detection Panels, Whole Body Cancer Screening Tests 2) By Targeted Multi-Cancer Panels: Organ Specific Cancer Panels, High Risk Population Screening Panels, Genetic Marker Based Panels, Epigenetic Marker Based Panels, Combination Biomarker Panels 3) By Single-Cancer Deoxyribonucleic Acid Blood Tests: Breast Cancer Detection Tests, Lung Cancer Detection Tests, Colorectal Cancer Detection Tests, Prostate Cancer Detection Tests, Liver Cancer Detection Tests

What Are The Drivers Of The Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market?

The increasing prevalence of cancer worldwide is expected to propel the growth of the multicancer early detection DNA blood tests market going forward.Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells that can invade surrounding tissues and, in advanced stages, metastasize to other parts of the body.The prevalence of cancer is increasing as global health systems report higher incidence rates and advancements in screening and detection technologies identify more cases at earlier stages.The multicancer early detection DNA blood tests support the rising prevalence of cancer by providing non-invasive, blood-based screening solutions that enable early identification of multiple cancer types through circulating tumor DNA analysis, improving early diagnosis and patient outcomes.For instance, in April 2024, according to the International Agency for Research on Cancer, a France-based intergovernmental organization forming part of the World Health Organization, there were almost 20 million new cases of cancer and close to 10 million deaths from cancer in 2022.Demographics-based predictions indicated that the annual number of new cancer cases will reach 35 million by 2050, representing a 77% increase from 2022.Therefore, the increasing prevalence of cancer worldwide is driving the growth of the multicancer early detection DNA blood tests market. The rising awareness of preventive healthcare is expected to propel the growth of the multicancer early detection DNA blood tests market going forward.Preventive healthcare refers to medical practices and strategies focused on disease prevention, early diagnosis, and health maintenance to reduce the risk of serious illnesses and improve long-term health outcomes.Awareness of preventive healthcare is increasing due to growing public health campaigns, expanding access to healthcare information, and rising emphasis on early disease detection and personalized medicine.Multicancer early detection DNA blood tests support preventive healthcare by offering non-invasive and convenient screening methods that enable the early identification of multiple cancer types through circulating tumor DNA analysis, helping improve treatment outcomes and survival rates.For instance, in January 2025, according to the Prevent Cancer Foundation, a US-based nonprofit organization focused on cancer prevention and early detection, participation in preventive cancer screening programs increased by 9.3% in 2024 compared to the previous year, reflecting growing public awareness and adoption of early detection practices.Therefore, the rising awareness of preventive healthcare is driving the growth of the multicancer early detection DNA blood tests market.

Key Players In The Global Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market

Major companies operating in the multicancer early detection deoxyribonucleic acid (dna) blood tests market are Thermo Fisher Scientific Inc., Prenetics Global Limited, Eurofins Scientific Inc., SeekIn Inc., VolitionRx Limited, Myriad Genetics Inc., Guardant Health, Freenome Holdings Inc., GENECAST Biotechnology Co. Ltd., Burning Rock Biotech Limited, Geneseeq Technology Inc.  , Quibim S. L., 1drop Inc., Bioneer Corporation, CellMax Life, Datar Cancer Genetics, Laboratory for Advanced Medicine Inc., Harbinger Health Inc., Norgen Biotek Corp., Singlera Genomics Inc., Elypta AB, StageZero Life Sciences, INOVIQ, AnPac Bio-Medical Science, EarlyDiagnostics, Micronoma

Global Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market Trends and Insights

Major companies operating in the multicancer early detection DNA blood tests market are focusing on developing innovative solutions, such as advancements in cell-free DNA (cfDNA) and methylation-based sequencing technologies, to meet the rising demand for early, non-invasive, and multi-cancer screening solutions. Cell-free DNA-based testing is the analysis of fragmented DNA released into the bloodstream by tumor cells, enabling the detection of multiple cancers from a single blood draw, unlike traditional diagnostic approaches that rely on invasive biopsies or organ-specific imaging techniques. For instance, in March 2025, Gene Solutions, a Vietnam-based biotechnology company, introduced an advanced multi-cancer early detection blood test designed for population-scale screening. The test utilizes cfDNA analysis combined with machine learning algorithms to identify cancer-specific genomic and epigenomic signatures across multiple cancer types. It enables early-stage cancer detection with high predictive accuracy while minimizing false positives, making it suitable for routine health screening. Additionally, the test incorporates tumor origin prediction technology to help identify the likely source of cancer for further diagnosis and is designed to improve accessibility to early cancer detection, particularly in regions with limited screening infrastructure.

Regional Insights

North America was the largest region in the multicancer early detection DNA blood tests market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market?

The multicancer early detection DNA blood tests market consists of revenues earned by entities by providing services such as cancer screening services, diagnostic testing services, genomic sequencing services, bioinformatics analysis services, laboratory testing services, and clinical interpretation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The multicancer early detection DNA blood tests market also includes sales of sequencing instruments, laboratory equipment, blood collection kits, reagents, assay kits, and sample preparation systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream laboratories, hospitals, diagnostic centers, distributors, and research institutions) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

What is the Market Assessment and Strategic Outlook for the Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Industry?

The multicancer early detection deoxyribonucleic acid (dna) blood tests market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the multicancer early detection deoxyribonucleic acid (dna) blood tests industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

What is the Market Assessment and Strategic Outlook for the Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market Report 2026?

The multicancer early detection deoxyribonucleic acid (DNA) blood tests market research report is one of a series of new reports from The Business Research Company that provides multicancer early detection deoxyribonucleic acid (DNA) blood tests market statistics, including multicancer early detection deoxyribonucleic acid (DNA) blood tests industry global market size, regional shares, competitors with a multicancer early detection deoxyribonucleic acid (DNA) blood tests market share, detailed multicancer early detection deoxyribonucleic acid (DNA) blood tests market segments, market trends and opportunities, and any further data you may need to thrive in the multicancer early detection deoxyribonucleic acid (DNA) blood tests industry. This multicancer early detection deoxyribonucleic acid (DNA) blood tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.